- This event has passed.
Consideration for Life Science Companies – Recent US Enforcement
2019/06/18 @ 6:00 PM - 8:00 PM
The United States has historically been the largest market for biopharmaceutical companies but China has been recognized as a biopharmaceutical growth driver. The life sciences sector faces extreme and unique challenges as drug development, biotechnology investment, and government regulations between the US and China have created hurdles against biopharma advancement in both countries. With greater biopharma investment being seen in both countries, businesses require an understanding of how to navigate some of these challenges, including government regulations, contract negotiations, and intellectual property. As many life sciences companies are keenly aware, the Foreign Investment Risk Review Modernization Act of 2018 (FIRMMA) provided sweeping change to the authority of the Committee on Foreign Investment in the United States (CFIUS), which has impacted Chinese foreign direct investment in biotechnology and life sciences and have contributed to significant reduction of Chinese investment in U.S. biotech companies. US Companies also face hurdles in entry to the Chinese market, collaboration deals in China, and IP hurdles. Life science companies must also stay keenly aware of US Food and Drug Administration (FDA) against China facilities that supply the US market with drugs and medical devices.
Join us and learn about recent developments and more in a panel featuring:
Bevin Newman, Healthcare Antitrust Partner at Sheppard Mullin Richter & Hampton
Grace Han McMahon, Executive Director, Transactions, Merck
Lawrence Kong, Senior Counsel at Amgen
Moderated by: Allison Fulton, FDA Regulatory Partner at Sheppard Mullin Richter & Hampton
Food and drinks will be provided, courtesy of Sheppard Mullin.
This activity has been approved for Minimum Continuing Legal Education credit by the State Bar of California. Sheppard Mullin Richter & Hampton LLP certifies that this activity conforms to the standards for approved education activities prescribed by the rules and regulations of the State Bar of California governing minimum continuing legal education.